Lushang Freda Pharmaceutical600223.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Lushang Freda Pharmaceutical (600223.SH) trades at a P/E of 35.30x, P/B of 1.34x, P/S of 1.49x, and a dividend yield of 1.02%.
Longitudinal percentile comparison: P/E sits at the 61st percentile over the trailing 10Y window (vs. 58th percentile over 3Y); P/B sits at the 9th percentile over the trailing 10Y window (vs. 8th percentile over 3Y); P/S sits at the 52nd percentile over the trailing 10Y window (vs. 5th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 50th percentile within its industry and the 48th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.02%, ranking at the 73rd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 52.6 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Lushang Freda Pharmaceutical operates in the Basic Chemical Engineering sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600223 · SSE: 600223 · 600223
Want the full picture on whether Lushang Freda Pharmaceutical (600223.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 35.30 | ||||||
| P/B (MRQ) | 1.34 | ||||||
| P/S (TTM) | 1.49 | ||||||
| Dividend Yield | 1.02% | ||||||
| Buyback + Div Yield | 1.02% |